- Home
- BXMX vs RCUS Comparison
BXMX vs RCUS Comparison
Compare BXMX & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXMX
- RCUS
- Stock Information
- Founded
- BXMX 2004
- RCUS 2015
- Country
- BXMX United States
- RCUS United States
- Employees
- BXMX N/A
- RCUS N/A
- Industry
- BXMX Investment Managers
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BXMX Finance
- RCUS Health Care
- Exchange
- BXMX Nasdaq
- RCUS Nasdaq
- Market Cap
- BXMX 1.5B
- RCUS 1.4B
- IPO Year
- BXMX N/A
- RCUS 2018
- Fundamental
- Price
- BXMX $13.69
- RCUS $15.52
- Analyst Decision
- BXMX
- RCUS Buy
- Analyst Count
- BXMX 0
- RCUS 12
- Target Price
- BXMX N/A
- RCUS $34.50
- AVG Volume (30 Days)
- BXMX 205.6K
- RCUS 755.7K
- Earning Date
- BXMX 01-01-0001
- RCUS 11-06-2024
- Dividend Yield
- BXMX 7.24%
- RCUS N/A
- EPS Growth
- BXMX N/A
- RCUS N/A
- EPS
- BXMX N/A
- RCUS N/A
- Revenue
- BXMX N/A
- RCUS $263,000,000.00
- Revenue This Year
- BXMX N/A
- RCUS $127.13
- Revenue Next Year
- BXMX N/A
- RCUS N/A
- P/E Ratio
- BXMX N/A
- RCUS N/A
- Revenue Growth
- BXMX N/A
- RCUS 119.17
- 52 Week Low
- BXMX $11.75
- RCUS $13.52
- 52 Week High
- BXMX $13.75
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- BXMX 33.81
- RCUS 44.11
- Support Level
- BXMX $14.14
- RCUS $14.78
- Resistance Level
- BXMX $14.14
- RCUS $18.07
- Average True Range (ATR)
- BXMX 0.15
- RCUS 0.96
- MACD
- BXMX -0.08
- RCUS -0.16
- Stochastic Oscillator
- BXMX 11.36
- RCUS 22.32
About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options strategy of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.